期刊文献+

Selection tool alpha-fetoprotein for patients waiting for liver transplantation: How to easily manage a fractal algorithm 被引量:3

Selection tool alpha-fetoprotein for patients waiting for liver transplantation: How to easily manage a fractal algorithm
下载PDF
导出
摘要 Alpha-fetoprotein(AFP) behavior in patients with hepatocellular carcinoma(HCC) waiting for liver transplant(LT) represents a perfect biological example of a fractal model in which its progressive modification and possible future prediction of its values are very hard to capture. As a consequence, AFP represents a useful but poorly manageable tool to increase the ability to better select HCC patients waiting for LT. Trying to find a "filrouge" in the recent literature, no definitive answers can be done to several open questions:(1) the best AFP value to adopt;(2) the best cut-off measurement; and(3) the best way to comfortably capture the effective, time-related, fluctuations of this biological marker. More, structured and prospective, studies using serial determination of AFP values within and without the context of locoregional therapies are needed in order to find the "ideal"(static and dynamic) cut-off values allowing to respond to all the still open questions in this field of transplant oncology. Alpha-fetoprotein (AFP) behavior in patients withhepatocellular carcinoma (HCC) waiting for liver transplant(LT) represents a perfect biological example of afractal model in which its progressive modification andpossible future prediction of its values are very hard tocapture. As a consequence, AFP represents a useful butpoorly manageable tool to increase the ability to betterselect HCC patients waiting for LT. Trying to find a "filrouge"in the recent literature, no definitive answers canbe done to several open questions (1) the best AFPvalue to adopt; (2) the best cut-off measurement; and(3) the best way to comfortably capture the effective,time-related, fluctuations of this biological marker.More, structured and prospective, studies using serialdetermination of AFP values within and without thecontext of locoregional therapies are needed in orderto find the "ideal" (static and dynamic) cut-off valuesallowing to respond to all the still open questions in thisfield of transplant oncology.
出处 《World Journal of Hepatology》 CAS 2015年第15期1899-1904,共6页 世界肝病学杂志(英文版)(电子版)
关键词 ALPHA-FETOPROTEIN Hepatocellular cancer MILAN criteria RECURRENCE DROP-OUT Alpha-fetoprotein Hepatocellular cancer Milan criteria Recurrence Drop-out
  • 相关文献

参考文献1

二级参考文献4

共引文献16

同被引文献118

  • 1Zou, Wei-Long,Zang, Yun-Jin,Chen, Xin-Guo,Shen, Zhong-Yang.Risk factors for fatal recurrence of hepatocellular carcinoma and their role in selecting candidates for liver transplantation[J].Hepatobiliary & Pancreatic Diseases International,2008,7(2):145-151. 被引量:17
  • 2Chang Liu,Guang-Qin Xiao,Lu-Nan Yan,Bo Li,Li Jiang,Tian-Fu Wen,Wen-Tao Wang,Ming-Qing Xu,Jia-Yin Yang.Value of α-fetoprotein in association with clinicopathological features of hepatocellular carcinoma[J].World Journal of Gastroenterology,2013,19(11):1811-1819. 被引量:22
  • 3John P. Duffy,Andrew Vardanian,Elizabeth Benjamin,Melissa Watson,Douglas G. Farmer,Rafik M. Ghobrial,Gerald Lipshutz,Hasan Yersiz,David S. K. Lu,Charles Lassman,Myron J. Tong,Jonathan R. Hiatt,Ronald W. Busuttil.Liver Transplantation Criteria For Hepatocellular Carcinoma Should Be Expanded: A 22-Year Experience With 467 Patients at UCLA[J].Annals of Surgery.2007(3)
  • 4Sung Hoon Yang,Kyung-Suk Suh,Hae Won Lee,Eung-Ho Cho,Jai Young Cho,Yong Beom Cho,In Hwan Kim,Nam-Joon Yi,Kuhn Uk Lee.A revised scoring system utilizing serum alphafetoprotein levels to expand candidates for living donor transplantation in hepatocellular carcinoma[J].Surgery.2007(5)
  • 5Pierre-Alain Clavien,Mickael Lesurtel,Patrick MM Bossuyt,Gregory J Gores,Bernard Langer,Arnaud Perrier.Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report[J]. Lancet Oncology . 2012 (1)
  • 6Josep M. Llovet,Jordi Bruix.Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival[J]. Hepatology . 2003 (2)
  • 7Anna S. Lok,James E. Everhart,Elizabeth C. Wright,Adrian M. Di Bisceglie,Hae–Young Kim,Richard K. Sterling,Gregory T. Everson,Karen L. Lindsay,William M. Lee,Herbert L. Bonkovsky,Jules L. Dienstag,Marc G. Ghany,Chihiro Morishima,Timothy R. Morgan.Maintenance Peginterferon Therapy and Other Factors Associated With Hepatocellular Carcinoma in Patients With Advanced Hepatitis C[J].Gastroenterology.2011(3)
  • 8Shu-Sen Zheng,Xiao Xu,Jian Wu,Jun Chen,Wei-Lin Wang,Min Zhang,Ting-Bo Liang,Li-Ming Wu.Liver Transplantation for Hepatocellular Carcinoma: Hangzhou Experiences[J].Transplantation.2008(12)
  • 9Shaheed Merani,Pietro Majno,Norman M. Kneteman,Thierry Berney,Philippe Morel,Gilles Mentha,Christian Toso.The impact of waiting list alpha-fetoprotein changes on the outcome of liver transplant for hepatocellular carcinoma[J].Journal of Hepatology.2011(4)
  • 10B. Pérez-Saborido,S. Jiménez de los Galanes,J.C. Menéu-Díaz,C. Jiménez Romero,A. Moreno Elola-Olaso,Y. Fundora Suárez,V. Barra Valencia,E. Moreno-González.Tumor Recurrence After Liver Transplantation for Hepatocellular Carcinoma: Recurrence Pathway and Prognostic Factors[J].Transplantation Proceedings.2007(7)

引证文献3

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部